A look at the top 10 nonprofit health systems by 2025 operating revenue
Digital Health

New publication on Hemopatch in Neurosurgery

Sponsored By Baxter Oct 6, 2025 8:00am
Digital Health


Postoperative complications can increase healthcare system costs. In neurosurgery postoperative cerebrospinal fluid (CSF) leakage or bleeding are some of those major complications. They increase the risk of infections for the patients, can cause reoperations or prolong the hospital stay.2,3

After its launch in Europe, New Zealand and Australia, the room temperature Hemopatch Sealing Hemostat just received a new publication in Frontiers in Surgery confirming the collagen pad’s ability and use as hemostat and dural sealant in neurosurgery. 4

The latest technical report* evaluated the effective use of Hemopatch Sealing Hemostat in Neurosurgery by a group of neurosurgeons from around the world.4 Hemopatch Sealing Hemostat is indicated for hemostasis and sealing in multiple specialties including Neurosurgery. The patch supports the achievement of hemostasis when conventional surgical techniques are not enough and can help achieve a watertight dural closure.

The conclusive and new feedback coming from the technical report* on the newest Hemopatch Sealing Hemostat configuration showed excellent tissue adherence on all evaluated defects and an improved tissue adherence of the new Hemopatch Sealing Hemostat configuration.

The new publication is another strong support to the long and well-evaluated clinical evidence of Hemopatch Sealing Hemostat. Its efficacy in neurosurgery has been described to reduce the incidence of CSF leaks when used as a dural sealant. 5-13 The use of such sealants demonstrates reducing hospital costs.4

*Pre-Clinical Data on animal models

For more information on Hemopatch sealing hemostat,  
Visit: https://advancedsurgery.baxter.eu/hemopatch 

INDICATIONS: Hemopatch Sealing Hemostat  is indicated as a hemostatic device and surgical sealant across various soft tissues (cardiovascular, connective tissue, parenchyma, serosa, viscera), and dura for procedures in which control of mild or moderate bleeding or leakage of other body fluids or air by conventional surgical techniques is either ineffective or impractical. Hemopatch Sealing Hemostat may be used to augment dura closure techniques to close small dural defects (≤3mm) following traumatic injury, excision, retraction or shrinkage of the dura mater. 

INTENDED PURPOSE: Hemopatch Sealing Hemostat is an absorbable collagen pad intended for sealing and hemostasis.

CONTRAINDICATIONS: Do not compress Hemopatch Sealing Hemostat into blood vessels or use intravascularly. The device must not be used in patients with known hypersensitivity to bovine proteins or brilliant blue (FD&C Blue No. 1 (Blue 1)). 

WARNINGS: Hemopatch Sealing Hemostat is not intended to be used in pulsatile, severe bleeding. The use of Hemopatch Sealing Hemostat is not recommended in the presence of an active infection. When used in, around, or in proximity to foramina in bone, areas of bony confine, the spinal cord, the brain and/or cranial nerves, care should be exercised to avoid overpacking (collagens may expand upon absorption of liquid), creating the potential for neural damage. Hemopatch Sealing Hemostat is not intended as a substitute for meticulous surgical technique and the proper application of ligatures or other conventional procedures for hemostasis and sealing.  

For safe and proper use of Hemopatch Sealing Hemostat, refer to full Instructions for Use.

Reference

  1. Hemopatch sealing hemostat Instructions for Use. 09/2024
  2. Hutter G, von Felten S, Sailer MH, Schulz M, Mariani L. Risk factors for postoperative CSF leakage after elective craniotomy and the efficacy of fleece-bound tissue sealing against dural suturing alone: a randomized controlled trial. J Neurosurg. (2014) 121:735–44. doi: 10.3171/2014.6.JNS131917
  3. Epstein NE. A review article on the diagnosis and treatment of cerebrospinal fluid fistulas and dural tears occurring during spinal surgery. Surg Neurol Int. (2013) 4: S301–17. doi: 10.4103/2152-7806.111427
  4. Rossmann J, Antunes ACM, Broc GG, Chan DTM, Chen S-Y, Dea N, Fairhall J, de Andrés Guijarro P, Montano N, Schebesch K-M, Timothy J and Yerramneni VK (2025) The PEG-coated collagen patch Hemopatch® for hemostasis and dural sealing in neurosurgery. Front. Surg. 12:1636372. doi: 10.3389/fsurg.2025.1636372
  5. Nowak S, Schroeder HWS, Fleck S. Hemopatch® as a new dural sealant: a clinical observation. Clin Neurol Neurosurg. (2019) 176:133–7. doi: 10.1016/j.clineuro.2018. 12.009
  6. Schebesch K-M, Brawanski A. Clinical experience with Hemopatch® as a dural sealant in cranial neurosurgery. Cureus. (2019) 11:e4013. doi: 10.7759/cureus.4013
  7. Prasad M, Mukerji N. Case report of a novel technique for repair of the vertebral artery during cranial surgery. Neurol Ther. (2019) 8:505–9. doi: 10.1007/s40120-019-0142-3
  8. Montano N, Giordano M, Caccavella VM, Ioannoni E, Polli FM, Papacci F, et al. Hemopatch® with fibrin glue as a dural sealant in cranial and spinal surgery. A technical note with a review of the literature. J Clin Neurosci. (2020) 79:144–7. doi: 10.1016/j.jocn.2020.07.011
  9. Diaz-Molina J, Martínez R, González-Vargas P, Calero L, Azevedo A, Conde C. Tisseel® versus Hemopatch® for dural sealing in neurosurgery. A prospective study in a tertiary center. Neurochirurgie. (2020) 66:429–34. doi: 10.1016/j.neuchi.2020.09.008
  10. Nowak S, Eördögh M, Schroeder HWS, Fleck S. Hemopatch® as a new dural sealant in posterior fossa neurosurgery; a clinical application observation. Int J Innov Surg. (2021) 4(1):1017.
  11. Sánchez Fernández C, Rodríguez-Arias CA. Evaluation of the safety and effectiveness of a sealant hemostatic patch for preventing cerebrospinal fluid leaks in cranial surgery. Expert Rev Med Devices. (2021) 18:1111–6. doi: 10.1080/17434440.2021.1988850
  12. Lombardo C, Lopez-Ben S, Boggi U, Gutowski P, Hrbac T, Krska L, et al. Hemopatch® is effective and safe to use: real-world data from a prospective European registry study. Updates Surg. (2022) 74:1521–31. doi: 10.1007/s13304-022-01353-y
  13. Schebesch K-M, Hrbac T, Jančálek R, Krska L, Marquez-Rivas J, Solar P. Realworld data on the usage of Hemopatch® as a hemostat and dural sealant in cranial and spinal neurosurgery. Cureus. (2023) 15:e34387. doi: 10.7759/cureus.34387

     

Manufacturer: 

Baxter Healthcare SA

Thurgauerstrasse 130 Glattbrugg, 

ZÜRICH, 8152 Switzerland 

Class of Device: III 

A black background with a black square AI-generated content may be incorrect.

This content is intended solely for healthcare professionals and should not be interpreted as medical advice. Please consult with a qualified healthcare provider for any health concerns.

Hemopatch sealing hemostat is approved for use only in selected countries. For specific information on the availability and regulatory status of Hemopatch sealing hemostat room temperature in your country, we recommend contacting your local Baxter Healthcare sales representative.

Baxter and Hemopatch are trademarks of Baxter International Inc. or its subsidiaries.

GBU-AS21-250029 (v1.0) 09/2025

The editorial staff had no role in this post's creation.
Digital Health